This activity is supported by an independent education grant from Genmab. This online education program has been designed solely for healthcare professionals in the USA. The information in this program is not suitable for any other country.

Join leading expert Dr. Joshua Brody for this accredited virtual workshop. This small-group, performance-focused workshop provides a case-based exploration of patient identification, treatment selection, and sequencing considerations for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Participants will engage in faculty-led case discussions, real-time polling, and decision-making exercises to evaluate referral pathways, assess patient and disease characteristics, and determine the optimal positioning of bispecific antibodies relative to CAR T-cell therapy and other emerging targeted treatment options in realistic community oncology settings.

This workshop is part of a series. Register for workshops 2, 3 and 4 below:

Workshop 2 - From Prescription to First Dose

Workshop 3 - Managing CRS, ICANS, and Infectious Complications

Workshop 4 - Building a Bispecific-Ready Practice

Session Highlights

• Apply evidence-based criteria to evaluate patient fitness, disease kinetics, and prior treatment responses when selecting second-line and subsequent therapies for R/R DLBCL and FL.
• Navigate complex clinical decision-making regarding CAR T-cell therapy referral versus community-based bispecific antibody initiation for vulnerable or logistically constrained patients.
• Differentiate the mechanisms of action, valencies, and structural characteristics of approved and investigational CD20xCD3 bispecific antibodies.
• Work through interactive real-world case scenarios requiring real-time patient identification and sequencing choices at critical clinical transition points.
• Formulate evidence-based clinical strategies that balance potential treatment toxicities, long-term therapeutic goals, and individual patient preferences.

Who Should Attend

This program is designed for:

• Community oncologists
• Community hematologists and hematology-oncologists
• Advanced practice providers (APPs)
• Nurse practitioners
• Oncology nurses
• Pharmacists
• Multidisciplinary care team members involved in treatment delivery and monitoring

Faculty

Joshua Brody, MD – Director of the Lymphoma Immunotherapy Program at the Mount Sinai Tisch Cancer Center in New York City. Since joining Mount Sinai in 2011, he has developed a robust clinical program, as well as a translational Cancer Immunotherapy Lab which investigates basic and applied tumor immunology for the development of novel therapies, particularly for lymphomas, breast cancer, and head/neck cancer with results published in top-tier journals, including Nature Medicine and Cancer Discovery.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

Joshua Brody, MD, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisor for AbbVie, AstraZeneca, BeOne, Genmab, Janssen, Merck, Regeneron, and Roche/Genentech; Consultant for AbbVie, AstraZeneca, BeOne, Genmab, Janssen, Merck, Regeneron, and Roche/Genentech; Speaker for AbbVie, AstraZeneca, BeOne, Genmab, Janssen, Merck, Regeneron, and Roche/Genentech.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until November 3, 2026. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 ANCC contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-26-344-L01-P

Type of Activity: Application

Fee information

There is no fee for this educational activity.